Natdac
Natdac is daclatasvir 60mg tablets for chronic hepatitis C, an NS5A inhibitor taken alongside a second direct-acting antiviral.
- Category
- Antivirals
- Active ingredient
- Daclatasvir
- Route
- Oral use
- Form
- Tablet
- Strengths
- 60mg
Prescription rules on Natdac vary by country.
Natdac details
- Condition
- Chronic Hepatitis C
- Therapeutic class
- Direct-Acting Antiviral
- Pharmacological class
- NS5A Inhibitor
- Contraindications
- hypersensitivity to active components
- Minor side effects
- fatigue; headache; nausea
- Moderate side effects
- insomnia; dizziness; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Natco Pharma
- Onset Time
- 1–2 weeks
- Duration
- 12–24 weeks
- Storage instructions
- Store in original packaging.
- Drug interactions
- amiodarone; rifampicin; st. john's wort
- Age restrictions
- For adults.
- Pregnancy and breastfeeding
- Pregnancy: Not recommended. Breastfeeding: Not recommended.
Precautions and warnings
monitor for hepatitis b reactivation; frequent monitoring of liver function; no alcohol consumption
Serious side effects
hepatitis b reactivation, requires immediate medical attention; severe bradycardia, requires immediate medical attention
Patient summary
Natdac is daclatasvir 60mg tablets for chronic hepatitis C, an NS5A inhibitor taken alongside a second direct-acting antiviral.
Mechanism of action
This combination therapy targets the HCV NS5A and NS5B proteins, inhibiting viral replication through multiple pathways. This multi-target approach is essential for achieving a sustained virological response.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Natdac
Natdac contains daclatasvir, an NS5A inhibitor used in the treatment of chronic hepatitis C. Produced by Natco Pharma, it is supplied as a 60mg tablet and is taken alongside sofosbuvir rather than on its own.
Natdac availability in Asia
Natdac is registered across five markets including Indonesia, Thailand and Malaysia, with availability also in the Philippines. Generic medicine produced in India often offers a more affordable alternative to the original brand for patients living far from well stocked city pharmacies. This therapy is intended for use under the guidance of a doctor to ensure appropriate care.